Practical pain relief strategies for people with DMD and their caregivers, covering daily care, medications, and emotional ...

DMD was first described by French neurologist Guillaume Benjamin Amand Duchenne in the 1860s. However, until the 1980s, little was known about the causes of any type of muscular dystrophy.

Late last year, the therapy developers dosed their first patient following positive preclinical data demonstrating safety and ...

From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

Families say it's 'completely frustrating' that children with Duchenne Muscular Dystrophy are being denied access to free ...

A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short ... condition that primarily affects boys. It causes relentless muscle breakdown, loss of mobility ...

The U.S. Food and Drug Administration gave Capricor Therapeutics' application on deramiocel priority review, with a decision ...

The symposium took place on 18 th March 2025, as part of the Muscular Dystrophy Association (MDA) Clinical & Scientific ...

further delaying his devastating Duchenne muscular dystrophy diagnosis. Amber Sapp [ Sapp family ] Duchenne is a fatal genetic disorder that causes progressive and irreversible muscle loss.

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

It causes relentless muscle breakdown ... Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy? Gene Therapy (2025). DOI: 10.1038/s41434-025-00531 ...